Dosaggio antibiotico pediatrico nell'ossigenazione extracorporea della membrana (PADECMO) (PADECMO)
Dosaggio antibiotico pediatrico nell'ossigenazione extracorporea della membrana
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The study will investigate whether - with the current dosing regimens of meropenem, piperacillin-tazobactam, amoxicillin-clavulanate, cephazolin, vancomycin, amikacin, teicoplanin and ciprofloxacin - pharmacodynamic targets are attained in a national multicentric clinical setting in pediatric patients on ECMO.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Pieter De Cock, PharmD
- Numero di telefono: +32 9 332 29 69
- Email: pieter.decock@uzgent.be
Luoghi di studio
-
-
-
Ghent, Belgio, 9000
- Reclutamento
- University Hospital
-
Contatto:
- Pieter De Cock
- Email: pieter.decock@uzgent.be
-
Leuven, Belgio, 3000
- Reclutamento
- Universitair hospital
-
Contatto:
- Debaveye Yves
- Email: yves.debaveye@uzleuven.be
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgio, 1020
- Reclutamento
- Queen Fabiola Children's University Hospital
-
Contatto:
- Biarent Dominique
- Email: dominique.biarent@huderf.be
-
Contatto:
- Vens Daphne
- Email: daphnevania.vens@huderf.be
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- patients admitted to the pediatric intensive care unit or cardiac intensive care unit
- patient age : 1,8 kg-15 years
- patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
- intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
- extracorporeal membrane oxygenation circuit
Exclusion Criteria:
- no catheter in place for blood sampling
- absence of parental/patient consent
- known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Altro: Amoxicillin-clavulanate
Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
Altri nomi:
|
|
Altro: Piperacillin-tazobactam
Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
Altri nomi:
|
|
Altro: Meropenem
Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving meropenem as part of routine clinical care.
Altri nomi:
|
|
Altro: Cefazolin
Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving cefazolin as part of routine clinical care.
Altri nomi:
|
|
Altro: Vancomycin
Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving vancomycin as part of routine clinical care.
Altri nomi:
|
|
Altro: Teicoplanin
Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving teicoplanin as part of routine clinical care.
Altri nomi:
|
|
Altro: Ciprofloxacin
Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
Altri nomi:
|
|
Altro: Amikacin
Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amikacin as part of routine clinical care.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amoxicillin, piperacillin, meropenem, cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Lasso di tempo: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen off extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Lasso di tempo: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Lasso di tempo: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for teicoplanin: probability of target attainment with the target being an Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration Ratio (AUC/MIC)
Lasso di tempo: up to 1 month
|
% of patients in whom an AUC/MIC of 900 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Lasso di tempo: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Lasso di tempo: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Lasso di tempo: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Lasso di tempo: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Lasso di tempo: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for beta-lactam antibiotics
Lasso di tempo: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a percentage of time during which the unbound concentration remains above the Minimal Inhibitory Concentration (MIC) of the micro-organism of at least 50% and a maximum concentration of 10 x MIC |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for ciprofloxacin
Lasso di tempo: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of ciprofloxacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 86 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for vancomycin
Lasso di tempo: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of vancomycin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 200 to 300 |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for teicoplanin
Lasso di tempo: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of teicoplanin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is an Area-under the concentration-Time Curve of 900 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for amikacin
Lasso di tempo: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of amikacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a peak over Minimal Inhibitory Concentration Ratio of 8 to 10, trough concentration below 5 mg/L and Area under the Concentration Time Curve/MIC>399 |
up to 1 month
|
|
Beta-lactam antibiotics (amoxicillin, piperacillin, meropenem, cefazolin): probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC)
Lasso di tempo: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in first dose conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Lasso di tempo: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Lasso di tempo: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Lasso di tempo: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Lasso di tempo: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Lasso di tempo: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Annick de Jaeger, MD, University Hospital, Ghent
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Peptidi
- Aminoacidi, peptidi e proteine
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Preparati farmaceutici
- Tecniche investigative
- Gestione dei campioni
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Forature
- Procedure chirurgiche, operative
- Carboidrati
- Glicosidi
- Amides
- Aminoglicosidi
- Glicoconiugati
- Combinazioni di droga
- Penicillina g
- beta-lattamici
- Lactams
- Acido clavulanico
- Acidi clavulanici
- Cefalosporine
- Tiazine
- Fluorochinoloni
- 4-chinoloni
- Chinoloni
- Chinolinine
- Solfoni
- Carbapenems
- Tienamycins
- Tazobactam
- Acido penicillanico
- Pipercillin
- Glicopeptidi
- Ampicillina
- Penicilline
- Kanamicina
- Lipoglicopeptidi
- Amoxicillina
- Meropenem
- Piperacillina, combinazione di farmaci Tazobactam
- Vancomicina
- Amikacina
- Cefazolina
- Combinazione di amoxicillina-potassio clavulanato
- Teicoplanina
- Ciprofloxacina
- Collezione di campioni di sangue
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- BC-03512 (EC 2015/0529)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .